Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- ChecktodayChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, showing the site branding and a minimal navigation. This indicates restricted access rather than an update to study data or page functionality.SummaryDifference20%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now includes a note about NIH grant/contract funding and the footer revision has been updated to v3.6.6.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page revision updated from v3.6.4 to v3.6.5, indicating a small update to the study record page.SummaryDifference0.1%

- Check57 days agoChange DetectedDifference0.1%

- Check78 days agoChange DetectedThe study record updated the status to Completed with no longer recruiting and posted results; enrollment is 33 with a completion date of 2026-03-12, and results were first posted on 2026-06-03, accompanied by expanded safety and response-criteria descriptions.SummaryDifference4%

- Check85 days agoChange DetectedThe revision tag on the page advanced from v3.6.0 to v3.6.2, signaling a backend/template update; no study content changes are involved.SummaryDifference0.1%

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.